TECHNOLOGY TRANSFER
Georgia State University’s Office of Technology Licensing & Commercialization works to ensure that great ideas find their way out of the lab and into the hands of the people who need them.
YEAR FOUNDED
2019
DEVELOPMENT STATUS
Preclinical
FUNDING SUPPORT
National Institutes of Health
Developing New Antiviral Treatments
Through its rich portfolio and notable partnerships, Precision BioPharma, Inc. is developing the next generation of antiviral treatments. The company uses adaptive translational research and artificial intelligence to rapidly identify and characterize new drugs and targets. Precision BioPharma’s team is comprised of seasoned experts in artificial intelligence, genomics, drug discovery and development, clinical trials and regulatory affairs.
Kumar is the inventor of Precision BioPharma’s leading antiviral drug candidate, PB-004. The company has submitted pre-IND application to the U.S. Food & Drug Administration for PB-004 and is planning clinical trials by the end of 2021.
—Mukesh Kumar
TECHNOLOGY TRANSFER
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.